{
    "clinical_study": {
        "@rank": "58805", 
        "arm_group": [
            {
                "arm_group_label": "Atorvastatin 20 mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Atorvastatin 80 mg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare the effects of 20 mg of atorvastatin to 80 mg of atorvastatin for\n      the prevention of atrial fibrillation after cardiothoracic surgery. The study hypothesis is\n      that 80 mg of atorvastatin will be more effective at preventing atrial fibrillation compared\n      to 20 mg."
        }, 
        "brief_title": "Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cardiothoracic Surgery", 
            "Post-operative Atrial Fibrillation"
        ], 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind comparison of two doses of atorvastatin for prevention of\n      post-operative atrial fibrillation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 19 or older\n\n          -  Undergoing elective cardiothoracic surgery\n\n        Exclusion Criteria:\n\n          -  Emergency cardiothoracic surgery\n\n          -  History of permanent atrial fibrillation\n\n          -  Acute coronary syndrome within 7 days\n\n          -  Antiarrhythmic drug use in the past 3 months\n\n          -  Receiving maximal tolerated dose of statin therapy\n\n          -  Receiving fibrate therapy\n\n          -  History of statin intolerance\n\n          -  Significant liver impairment (aspartate aminotransferase/alanine\n             aminotransferase(AST/ALT)>2x ULN)\n\n          -  Serum Creatinine > 3 mg/dl\n\n          -  Pregnancy or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029534", 
            "org_study_id": "13-16729"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atorvastatin 20 mg", 
                "intervention_name": "Atorvastatin 20 mg", 
                "intervention_type": "Drug", 
                "other_name": "Lipitor"
            }, 
            {
                "arm_group_label": "Atorvastatin 80 mg", 
                "intervention_name": "Atorvastatin 80 mg", 
                "intervention_type": "Drug", 
                "other_name": "Lipitor"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "post-operative atrial fibrillation", 
            "POAF", 
            "A-Fib"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Omaha", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68131"
                }, 
                "name": "Creighton University"
            }, 
            "investigator": [
                {
                    "last_name": "Aiman Smer, MBBCh", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Manu Kaushik, MBBS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Janardhana Gorthi, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Daniel E Hilleman, PharmD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hussam Abuissa, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tammy L Burns, PharmD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Aryan N Mooss, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation", 
        "overall_contact": {
            "email": "tammyburns@creighton.edu", 
            "last_name": "Tammy Burns, PharmD, BCPS", 
            "phone": "402-280-4292"
        }, 
        "overall_official": {
            "affiliation": "Creighton University", 
            "last_name": "Aiman Smer, MBBCh", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Occurrence of atrial fibrillation, defined as a new diagnosis of atrial fibrillation that lasts at least 5 minutes based on telemetry or 12 lead ECG readings.", 
            "measure": "Occurrence of atrial fibrillation by hospital discharge", 
            "safety_issue": "No", 
            "time_frame": "Hospital discharge, an expected 5-7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029534"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Length of hospital stay", 
                "safety_issue": "No", 
                "time_frame": "Hospital discharge, an expected 5-7 days"
            }, 
            {
                "measure": "Incidence of major adverse cardiac and cardiovascular events (MACCE) at 30 days", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Creighton University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Creighton University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}